Acta Pharmaceutica Sinica. B最新文献_第4页

Oral artificial microbio-vaccine triggers synergistic immunogenic cell death induction and tumor microenvironment remodeling for liver cancer therapy 口服人工微生物疫苗协同免疫原性细胞死亡诱导和肿瘤微环境重塑治疗肝癌

IF 14.6 1区医学

Acta Pharmaceutica Sinica. B Pub Date : 2026-10-01 Epub Date: 2026-07-04 DOI: 10.1016/j.apsb.2026.06.058

Qian Cheng, Siyao Li, Lu Deng, Li Xiong, Huiling Hu, Jingjing Li, Lele Zhang, Boda Guo, Chuan Zheng, Jinming Zhang

{"title":"Oral artificial microbio-vaccine triggers synergistic immunogenic cell death induction and tumor microenvironment remodeling for liver cancer therapy","authors":"Qian Cheng, Siyao Li, Lu Deng, Li Xiong, Huiling Hu, Jingjing Li, Lele Zhang, Boda Guo, Chuan Zheng, Jinming Zhang","doi":"10.1016/j.apsb.2026.06.058","DOIUrl":"10.1016/j.apsb.2026.06.058","url":null,"abstract":"<div><div>Artificial cellular systems, engineered to mimic biological functions, offer a promising platform for advanced drug delivery and immunotherapy. Translating such systems into effective oral tumor vaccines, however, remains challenging due to the harsh gastrointestinal environment, inefficient immune activation, and the toxicity of potent immunogenic agents. To overcome these barriers, we engineered an oral artificial micro bio-vaccine <em>via</em> a hierarchical assembly strategy. Triptolide (TP), an immunogenic cell death inducer, was co-assembled with glycyrrhizic acid (GA), an immunomodulator, into a nanodetoxifying core to facilitate efficient loading into hollow <em>Saccharomyces cerevisiae</em> microcapsules (YC), forming the final aggregate (TP/GA-NYPs). This rational design leverages the YC for gastric protection and gut mucosa-targeting, while the Chitosan shell ensures robust encapsulation. Crucially, the TP/GA core demonstrates a synergistic interplay, in which TP potently induces immunogenic cell death, while GA concurrently remodels the immunosuppressive tumor microenvironment by suppressing metastasis-related markers and enhancing immunostimulatory cytokine profiles. This spatiotemporally coupled action within a single oral aggregate elicits robust intestinal mucosal and systemic immunity, effectively suppressing liver cancer progression and metastasis while mitigating the systemic toxicity of TP. This work highlights the therapeutic potential of functional aggregates in orchestrating synergistic anti-tumor immunity and offers a versatile platform for oral immunotherapy.</div></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"16 10","pages":"Pages 6924-6942"},"PeriodicalIF":14.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149204903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lysosomal membrane damage repair and acidification impairment restoration triggered by smart lipid nanoparticles for Alzheimer's disease treatment 用于阿尔茨海默病治疗的智能脂质纳米颗粒引发的溶酶体膜损伤修复和酸化损伤恢复

IF 14.6 1区医学

Acta Pharmaceutica Sinica. B Pub Date : 2026-10-01 Epub Date: 2026-06-22 DOI: 10.1016/j.apsb.2026.06.036

Jiaqing Yin, Wei Lv, Wei Zhao, Zhenwei Ding, Fei Zhu, Hongli Liu, Shengnan Li, Xiang Cao, Linfeng Liu, Kefan Song, Yue Gong, Jiangna Xu, Yuqin Chen, Zhiyuan Zhang, Xiangming Fang, Hongliang Xin

{"title":"Lysosomal membrane damage repair and acidification impairment restoration triggered by smart lipid nanoparticles for Alzheimer's disease treatment","authors":"Jiaqing Yin, Wei Lv, Wei Zhao, Zhenwei Ding, Fei Zhu, Hongli Liu, Shengnan Li, Xiang Cao, Linfeng Liu, Kefan Song, Yue Gong, Jiangna Xu, Yuqin Chen, Zhiyuan Zhang, Xiangming Fang, Hongliang Xin","doi":"10.1016/j.apsb.2026.06.036","DOIUrl":"10.1016/j.apsb.2026.06.036","url":null,"abstract":"<div><div>Alzheimer's disease (AD), characterized by amyloid (A<em>β</em>) deposition in neurons, is the most serious neurodegenerative disorder, but lacks effective therapeutic drugs in the clinic. Impaired neuronal lysosomal function drives the pathological accumulation of intracellular A<em>β</em>. Targeted rehabilitation of lysosomal dysfunction may offer a potential strategy to restore neuronal homeostasis and mitigate AD progression. In this study, we developed a brain-targeted smart lipid nanoparticle (A-PSL@7BIO) to repair lysosomal membrane damage and restore impaired acidification in the brain for AD therapy. The system was composed of Angiopep-2 peptide-conjugated lipid nanoparticles, which were loaded with a Glycogen synthase kinase-3<em>β</em> (GSK-3<em>β</em>) inhibitor 7-bromoindirubin-3ʹ-oxime (7BIO) and incorporated with dipalmitoyl-phosphatidylserine (DPPS) and a reactive oxygen species (ROS) responsive phospholipid. Through Angiopep-2-mediated blood–brain barrier (BBB) transcytosis, the smart lipid nanoparticles could enhance brain biodistribution with subsequent neuronal internalization. Pathologically elevated intracellular ROS levels in AD could induce stimulus-responsive payload release, wherein 7BIO selectively inhibited aberrant GSK-3<em>β</em> hyperphosphorylation to restore the physiological acidic lysosomal environment and DPPS structurally repaired compromised lysosomal membranes, synergistically addressing dual aspects of lysosomal pathology. This smart lipid nanoparticles synergistically restored physiological lysosomal homeostasis, reversed neuronal dysfunction, and ameliorated cognitive deficits in AD models, indicating that A-PSL@7BIO could be used as a potential nanomedicine for AD therapy.</div></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"16 10","pages":"Pages 7037-7053"},"PeriodicalIF":14.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149205249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Antibody peptide conjugates as multifunctional therapeutics: Mechanisms, challenges, and prospects 抗体肽偶联物作为多功能疗法：机制、挑战和前景

IF 14.6 1区医学

Acta Pharmaceutica Sinica. B Pub Date : 2026-10-01 Epub Date: 2026-08-03 DOI: 10.1016/j.apsb.2026.07.049

Fei Xie, Lianqi Liu, Qi Cheng, Dian Xiao, Xinbo Zhou, Song Li

{"title":"Antibody peptide conjugates as multifunctional therapeutics: Mechanisms, challenges, and prospects","authors":"Fei Xie, Lianqi Liu, Qi Cheng, Dian Xiao, Xinbo Zhou, Song Li","doi":"10.1016/j.apsb.2026.07.049","DOIUrl":"10.1016/j.apsb.2026.07.049","url":null,"abstract":"<div><div>Antibody peptide conjugates (APCs) represent a newly emerging class of targeted biotherapeutics that embody a novel structural paradigm by combining the precise targeting capabilities of antibodies with the versatile biological functions of peptides. APCs not only overcome the inherent limitations of conventional peptide therapeutics but also go beyond the cytotoxicity-focused paradigm of traditional antibody drug conjugates (ADCs). By flexibly combining peptide payload activities with antibody functions, APCs have developed into diverse therapeutic strategies, including immunomodulation, targeted antibacterial, and targeted protein degradation, among others. Several APCs have already achieved notable progress and entered clinical studies, underscoring their potential as a next-generation targeted therapeutic platform. In this review, we present the first comprehensive structural framework for APCs, defining seven distinct subtypes and discussing their biological mechanisms, structure–activity relationships, recent advances, and major challenges. Furthermore, we propose guiding principles for the rational design of APCs and highlight future research directions, aiming to accelerate progress in this rapidly developing field of innovative therapeutics.</div></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"16 10","pages":"Pages 6553-6573"},"PeriodicalIF":14.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149204644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unnatural amino acid-based miniPROTACs enable efficient oncoprotein degradation 基于非天然氨基酸的miniPROTACs能够有效地降解癌蛋白

IF 14.6 1区医学

Acta Pharmaceutica Sinica. B Pub Date : 2026-10-01 Epub Date: 2026-03-02 DOI: 10.1016/j.apsb.2026.02.022

Jianchao Zhang, Xiao Chen, Congli Chen, Fengming Li, Kefan Liao, Xiaoxiao Song, Ya Zeng, Jie Wang, Ming-Yuan Su, Chris Soon Heng Tan, Lijing Fang, Hai Rao

{"title":"Unnatural amino acid-based miniPROTACs enable efficient oncoprotein degradation","authors":"Jianchao Zhang, Xiao Chen, Congli Chen, Fengming Li, Kefan Liao, Xiaoxiao Song, Ya Zeng, Jie Wang, Ming-Yuan Su, Chris Soon Heng Tan, Lijing Fang, Hai Rao","doi":"10.1016/j.apsb.2026.02.022","DOIUrl":"10.1016/j.apsb.2026.02.022","url":null,"abstract":"<div><div>Proteolysis-targeting chimeras (PROTACs) harness the cell's proteolytic systems to eliminate harmful proteins for therapeutic purposes. Unnatural amino acids (UAAs) offer unique structural features for drug design but have not yet been applied to targeted protein degradation. Here, we develop a set of linker-free PROTACs in which Lys-derived UAAs—ornithine (Orn) and 2,4-diaminobutyric acid (Dab)—serve as degrons that are directly conjugated to target ligands, yielding compact and effective degraders. Both Orn-BA and Dab-BA promote the efficient degradation of EML4-ALK, with Dab-BA exhibiting superior potency, attributed to its enhanced ability to promote ternary complex formation with the target and E3 ligase. Dab-BA also significantly suppresses tumor growth in a xenograft mouse model. The general applicability of this UAA-based linker-free PROTAC approach is further demonstrated by the development of BCR-ABL degraders. Our study represents the first application of UAAs in targeted protein degradation and offers a complementary strategy for E3 ligand discovery.</div></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"16 10","pages":"Pages 6814-6830"},"PeriodicalIF":14.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149204671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Stimulate-and-retain hydrogel strategy integrating oncolytic virus and oxaliplatin for dual ICD-inducing antitumor immunity 结合溶瘤病毒和奥沙利铂的刺激和保留水凝胶策略双重诱导icd抗肿瘤免疫

IF 14.6 1区医学

Acta Pharmaceutica Sinica. B Pub Date : 2026-10-01 Epub Date: 2026-07-29 DOI: 10.1016/j.apsb.2026.07.040

Dan Zhang, Anxian Chen, Haimeng Huang, Wenjing Li, Qili Huang, Hongzhong Chen, Jiaxing Zhang, Li Yang, Caijun Sun, Xiaowei Zeng

{"title":"Stimulate-and-retain hydrogel strategy integrating oncolytic virus and oxaliplatin for dual ICD-inducing antitumor immunity","authors":"Dan Zhang, Anxian Chen, Haimeng Huang, Wenjing Li, Qili Huang, Hongzhong Chen, Jiaxing Zhang, Li Yang, Caijun Sun, Xiaowei Zeng","doi":"10.1016/j.apsb.2026.07.040","DOIUrl":"10.1016/j.apsb.2026.07.040","url":null,"abstract":"<div><div>Immunogenic cell death (ICD) provides a promising strategy for cancer treatment by stimulating anti-tumor immunity. However, single ICD inducers often elicit insufficient damage-associated molecular patterns (DAMPs), and the rapid clearance of these DAMPs at the tumor site further prevents sustained immune stimulation. To address these challenges, we developed a polyphenol-based bioadhesive hydrogel antigen reservoir functionalized with dopamine (DA) and loaded with dual ICD inducers. Specifically, thymidine kinase (tk)-deficient oncolytic vaccinia virus (VV, a type II ICD inducer) was combined with oxaliplatin (OXA, a type I ICD inducer), thereby enhancing direct tumor cytotoxicity and synergistically amplifying ICD through distinct mechanisms to promote robust DAMP release. Subsequently, the released DAMPs were captured and retained by the DA-functionalized hyaluronic acid-Pluronic® F127 hydrogel (HADP), forming an antigen reservoir at the tumor site. This synergistic “stimulate-and-retain” strategy not only augments ICD-mediated DAMP release but also prolongs their local availability to sustain immune stimulation. In murine models, the OXA-HADP@VV facilitated dendritic cell (DC) activation, increased IFN-<em>γ</em><sup>+</sup>CD8<sup>+</sup> T cell infiltration, and reduced regulatory T cells (Tregs), thereby achieving effective tumor suppression and strong anti-recurrence effects. Together, this dual ICD-inducing antigen reservoir provides a versatile platform for improving cancer immunotherapy.</div></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"16 10","pages":"Pages 6943-6957"},"PeriodicalIF":14.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149205208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Author correction to “Hollow copper sulfide nanoparticles carrying ISRIB for the sensitized photothermal therapy of breast cancer and brain metastases through inhibiting stress granule formation and reprogramming tumor-associated macrophages” [Acta Pharmaceutica Sinica B 13 (2023) 3471–3488] 作者对“携带ISRIB的中空硫化铜纳米颗粒通过抑制应激颗粒形成和肿瘤相关巨噬细胞重编程用于乳腺癌和脑转移的敏化光热治疗”的修正[药物学报B 13 (2023) 3471-3488]

IF 14.6 1区医学

Acta Pharmaceutica Sinica. B Pub Date : 2026-10-01 Epub Date: 2026-07-17 DOI: 10.1016/j.apsb.2026.07.028

Fan Tong, Haili Hu, Yanyan Xu, Yang Zhou, Rou Xie, Ting Lei, Yufan Du, Wenqin Yang, Siqin He, Yuan Huang, Tao Gong, Huile Gao

引用次数: 0

Antibody‒cell conjugates: A novel “off-the-shelf” modality bridging ADCs and CAR-T for cancer immunotherapy 抗体-细胞偶联物：一种新型的“现成的”桥接adc和CAR-T用于癌症免疫治疗的方式

IF 14.6 1区医学

Acta Pharmaceutica Sinica. B Pub Date : 2026-10-01 Epub Date: 2026-07-25 DOI: 10.1016/j.apsb.2026.07.034

Yifei Dai, Yujia Xie, Xiaojuan Ma, Dong Zhang, Jiao Yang, Kequan Lin, Aiping Chen, Weijie Qiang

{"title":"Antibody‒cell conjugates: A novel “off-the-shelf” modality bridging ADCs and CAR-T for cancer immunotherapy","authors":"Yifei Dai, Yujia Xie, Xiaojuan Ma, Dong Zhang, Jiao Yang, Kequan Lin, Aiping Chen, Weijie Qiang","doi":"10.1016/j.apsb.2026.07.034","DOIUrl":"10.1016/j.apsb.2026.07.034","url":null,"abstract":"<div><div>Antibody‒cell conjugates (ACCs) represent a promising therapeutic strategy emerging in the biopharmaceutical industry to overcome the limitations of current immunotherapies. ACCs constitute a novel class of living drugs developed by anchoring functional antibodies onto the surface of living cells <em>via</em> specific linkers or conjugation methods. These carrier cells encompass both immune effector cells (such as Natural Killer cells, <em>γδ</em> T cells, and activated T cells) and non-immune cells (such as erythrocytes and platelets). Distinct from genetic engineering, ACCs directly modify the cell surface using chemical biology, enzymatic catalysis, or physical assembly, thereby endowing cells with precise tumor-targeting capabilities while preserving their intrinsic biological functions. This technology facilitates the scalable production of “off-the-shelf” therapeutics and has shown promising potential in treating both hematological malignancies and refractory solid tumors with a superior safety profile. This review systematically examines the current construction strategies and carrier cell selection for ACCs, covering both immune effector cells and non-immune carrier cells, and discusses the clinical progress, key challenges, and future directions.</div></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"16 10","pages":"Pages 6360-6377"},"PeriodicalIF":14.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149205276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

In vivo validation of intramolecular bivalent glues targeting PSMA reveals potent and tissue-selective BRD4 degradation in prostate cancer 靶向PSMA的分子内二价胶的体内验证揭示了前列腺癌中BRD4的有效和组织选择性降解

IF 14.6 1区医学

Acta Pharmaceutica Sinica. B Pub Date : 2026-10-01 Epub Date: 2026-08-11 DOI: 10.1016/j.apsb.2026.08.008

Deqin Cai, Chunrong Li, Malick Bio Idrissou, Nina J. Hawkins, Ramesh Mudududdla, Xuankun Chen, Thao-Vy T. Nguyen, Xiaolei Li, Reinier Hernandez, Weiping Tang

{"title":"In vivo validation of intramolecular bivalent glues targeting PSMA reveals potent and tissue-selective BRD4 degradation in prostate cancer","authors":"Deqin Cai, Chunrong Li, Malick Bio Idrissou, Nina J. Hawkins, Ramesh Mudududdla, Xuankun Chen, Thao-Vy T. Nguyen, Xiaolei Li, Reinier Hernandez, Weiping Tang","doi":"10.1016/j.apsb.2026.08.008","DOIUrl":"10.1016/j.apsb.2026.08.008","url":null,"abstract":"<div><div>Various approaches have been explored to address the on-target, off-tissue toxicity of PROTACs and molecular glues, but most fall short in achieving robust <em>in vivo</em> selectivity and efficacy. In this study, we introduce a delivery strategy that enables tissue-selective deployment of an ultra-potent, picomolar-active DCAF16-recruiting intramolecular bivalent glue (<strong>IBG3</strong>) for BRD4 degradation in prostate cancer models by targeting the prostate-specific membrane antigen (PSMA). We first introduced rational modifications to <strong>IBG3</strong> to install a suitable conjugation handle for PSMA ligand attachment, and incorporated a cathepsins-sensitive cleavable linker together with a dual functional polycarboxylate linker that enhances PSMA binding while suppressing passive diffusion. Selective BRD4 degradation was validated by multiple orthogonal assays <em>in vitro</em> and <em>in vivo.</em> The lead conjugate <strong>IBG-P3</strong> achieved 79.8% tumor growth inhibition at 0.01 mg/kg in PC3-PIP xenografts, while an epimeric control lacking PSMA binding was inactive. Importantly, robust antitumor efficacy was further confirmed in an endogenous PSMA-expressing LNCaP xenograft model, where <strong>IBG-P3</strong> achieved 72.6% tumor growth inhibition at a dose as low as 0.001 mg/kg, significantly outperforming the parent compound <strong>IBG3</strong>. This study provides the first <em>in vivo</em> validation of IBG degrader and establishes a preclinical framework for PSMA-guided delivery of potent degraders.</div></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"16 10","pages":"Pages 6905-6923"},"PeriodicalIF":14.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149205279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Molecular mechanisms, crosstalk and therapeutic potential of novel acylation modifications in cardiovascular and cerebrovascular diseases 新型酰化修饰在心脑血管疾病中的分子机制、串扰和治疗潜力

IF 14.6 1区医学

Acta Pharmaceutica Sinica. B Pub Date : 2026-10-01 Epub Date: 2026-06-29 DOI: 10.1016/j.apsb.2026.06.051

Wanchun Li, Weile Ye, Jiaojiao Wang, Zhiping Liu

{"title":"Molecular mechanisms, crosstalk and therapeutic potential of novel acylation modifications in cardiovascular and cerebrovascular diseases","authors":"Wanchun Li, Weile Ye, Jiaojiao Wang, Zhiping Liu","doi":"10.1016/j.apsb.2026.06.051","DOIUrl":"10.1016/j.apsb.2026.06.051","url":null,"abstract":"<div><div>Metabolic reprogramming, the fundamental process by which cells adapt to fluctuations in energy demands, is pivotal in the pathophysiology of cardiovascular and cerebrovascular diseases (CCVDs). Aberrant reprogramming of glucose, lipid, and amino acid metabolism is intricately associated with pathological processes in CCVDs such as cardiac hypertrophy, atherosclerosis, and ischemia-reperfusion injury. This metabolic remodeling disrupts the dynamic balance of metabolites (cc, acetyl-CoA and lactate) in the cardio-cerebrovascular systems, thereby inducing abnormal post-translational modifications (PTMs) on histones and non-histone proteins. These PTMs drive disease progression by modulating gene transcription or the activity of key proteins, which subsequently influences downstream signaling pathways. Here, we systematically examine the regulatory enzymes and functional roles of nine recently characterized acylation modifications: crotonylation, <em>β</em>-hydroxybutyrylation, 2-hydroxyisobutyrylation, succinylation, malonylation, glutarylation, lactylation, propionylation, and butyrylation. Furthermore, this review elaborates on the molecular mechanisms, crosstalk and the latest preclinical advancements regarding these acylations in CCVDs, emphasizing the influence of distinct acylation patterns on various pathological processes and highlighting the clinical translational prospects of targeting these novel modifications for therapeutic intervention.</div></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"16 10","pages":"Pages 6432-6461"},"PeriodicalIF":14.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149205205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Illuminating the black box: Mapping the fates of polymeric micelle drug carriers in vivo 照亮黑箱：绘制体内高分子胶束药物载体的命运

IF 14.6 1区医学

Acta Pharmaceutica Sinica. B Pub Date : 2026-10-01 Epub Date: 2026-10-16 DOI: 10.1016/j.apsb.2026.09.012

Xinxin Ding

引用次数: 0